Research ReportMay 26, 2026
AI Research Insights
Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
Research ReportMay 26, 2026
Dosing and Safety Considerations for Bleomycin-, Etoposide-, and Platinum-Based Regimens in Testicular Cancer: Practical Guidance for Current Practice
Chemotherapy regimens, dosing and monitoring for GCT focus on safety and long-term care.
Research ReportMay 26, 2026
Testicular Germ Cell Tumors 2021–2026: Biomarker Advances, De‑escalation, and the Implementation Gap in Europe and China
Novel biomarkers and tailored strategies advance TGCT care with global adoption barriers
Research ReportMay 25, 2026
BEP × 3 versus EP × 4 for IGCCCG Good‑Risk Testicular Germ Cell Tumors After Orchiectomy: An Evidence‑Based Narrative Review
Two regimens treat favorable GCT, balancing efficacy and distinct toxic risks
Research ReportMay 25, 2026
HIF‑2α Inhibitors in RCC and VHL‑Associated Tumors: A 2026 Global Competitive Review Benchmarked to Belzutifan
HIF‑2α inhibitors: Belzutifan leads; casdatifan/NKT2152 follow, with wide RCC/VHL whitespace.
Research ReportMay 25, 2026
Global Clinical-Stage Landscape in Urothelial Bladder Cancer (as of 2026-05-20)
UBC treatment evolves fast with ADC, ICI; FGFR and CAR-T remain vacant
Research ReportMay 22, 2026
Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-Based Chemotherapy as First-Line Therapy for Locally Advanced or Metastatic Urothelial Carcinoma: An Evidence-Based Narrative Review
EV plus pembrolizumab is the optimal first-line regimen for most advanced urothelial carcinoma patients, with platinum chemotherapy reserved for specific high-risk cases.
Research ReportMay 22, 2026
A Practical Biomarker Framework for Urothelial Bladder Cancer: Predictive Response, Resistance, Pharmacodynamic Engagement, and Safety Stratification in the Era of Precision Oncology
Biomarkers guide precise targeted therapy and safety management for urothelial bladder cancer.
Research ReportMay 22, 2026
A Practical Biomarker Framework for Urothelial Bladder Cancer: Predictive Response, Resistance, Pharmacodynamic Engagement, and Safety Stratification in the Era of Precision Oncology
Biomarkers guide precise targeted therapy and safety management for urothelial bladder cancer.
Research ReportMay 22, 2026
First-line systemic therapy for unresectable malignant pleural mesothelioma: platinum/pemetrexed chemotherapy versus nivolumab plus ipilimumab
Nivo+ipi beats chemo for unresectable MPM, especially non-epithelioid.
Research ReportMay 22, 2026
Transformative Advances in Multiple Myeloma (2023–May 2026): A Practice-Facing Narrative Review
MM care evolves with CAR-T, bispecifics, and MRD-driven strategies.
Research ReportMay 22, 2026
Unmet Needs and Practice Gaps in Bladder Cancer Management in China: A Narrative Review
Systemic flaws hinder standardized bladder cancer treatment across China.
Research ReportMay 21, 2026
A Narrative Biomarker Framework for Pleural and Peritoneal Mesothelioma: Diagnostic, Prognostic, Predictive, and Translational Integration
Biomarkers serve multi-layered roles in mesothelioma diagnosis, prognosis and targeted therapy.
Research ReportMay 21, 2026
Daratumumab + Lenalidomide + Dexamethasone versus Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Benefit–Risk Assessment
Dara-Rd vs VRd: efficacy, safety, and QoL differ in TIE NDMM.
Research ReportMay 21, 2026
Unmet Needs and Practice Gaps in Malignant Pleural and Peritoneal Mesothelioma Management: A Narrative Review Across China, the United States, and Europe
Global mesothelioma care faces four key unmet needs.
Research ReportMay 21, 2026
Multiple Myeloma Therapy in China versus the United States (2025–2026): Standards of Care, Care Pathways, and Access Realities
MM care converges in US/China, with access gaps shaping real-world practice.
Research ReportMay 21, 2026
Epidemiology of Multiple Myeloma: Global Burden, Regional Variation, and Clinical Implications
MM shows rising global burden with obvious regional, demographic disparities and varied risk factors
Research ReportMay 9, 2026
Precision Medicine in High-Burden Cancers: Molecular Innovation Amid Persistent Access and Outcome Disparities
Precision oncology has advanced across major cancers, yet inequitable biomarker testing, reimbursement, and infrastructure constrain real-world therapeutic access.
Research ReportMay 9, 2026
Global Epidemiology of Lung, Breast, Colorectal, and Prostate Cancers in 2024: Incidence, Mortality, Regional Disparities, and Driving Factors
Global cancer burden is rising, with marked regional disparities driven by screening access, treatment capacity, socioeconomic development, and modifiable risk exposures.
Research ReportMay 9, 2026
Obesity, Type 2 Diabetes Mellitus, and Endometrial Cancer: Metabolic-Endocrine Mechanisms and the Evolving Evidence for Metformin Chemoprevention
Obesity and T2DM promote endometrial carcinogenesis via metabolic-endocrine dysregulation; metformin shows mechanistic promise but lacks definitive preventive evidence.